Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$1.80 USD
+0.04 (2.02%)
Updated Apr 26, 2024 09:59 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Sonnet BioTherapeutics Holdings, Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 30 |
Cost Of Goods | 0 | 0 | 0 | 0 | 9 |
Gross Profit | 0 | 0 | 0 | 0 | 21 |
Selling & Adminstrative & Depr. & Amort Expenses | 19 | 30 | 26 | 24 | 37 |
Income After Depreciation & Amortization | -19 | -30 | -25 | -24 | -16 |
Non-Operating Income | 0 | 0 | 0 | 0 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -19 | -30 | -25 | -24 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | -1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -19 | -30 | -25 | -24 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | -1 |
Net Income (GAAP) | -19 | -30 | -25 | -24 | -18 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -19 | -30 | -25 | -24 | -13 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 4 |
Income After Depreciation & Amortization | -19 | -30 | -25 | -24 | -16 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 1.04 | NA | NA | 0.03 | NA |
Diluted EPS Before Non-Recurring Items | -18.14 | NA | NA | -1,920.77 | NA |
Diluted Net EPS (GAAP) | -18.14 | -150.33 | -313.97 | -2,142.40 | NA |
Fiscal Year end for Sonnet BioTherapeutics Holdings, Inc falls in the month of September.
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.02 | 0.04 | 0.04 | 0.04 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.02 | 0.04 | 0.04 | 0.04 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.29 | 3.63 | 3.95 | 5.70 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.27 | -3.59 | -3.91 | -5.66 |
Non-Operating Income | NA | 0.11 | -0.08 | -0.03 | 0.00 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.17 | -3.68 | -3.95 | -5.67 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.17 | -3.68 | -3.95 | -5.67 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.17 | -3.68 | -3.95 | -5.67 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 3.80 | NA | 1.34 | 0.75 |
Diluted EPS Before Non-Recurring Items | NA | -0.31 | NA | -2.86 | -7.47 |
Diluted Net EPS (GAAP) | NA | -0.31 | 9.77 | -2.86 | -7.47 |